Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

385 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical, Angiographic, and Procedural Correlates of Very Late Absorb Scaffold Thrombosis: Multistudy Registry Results.
Ellis SG, Gori T, Serruys PW, Nef H, Steffenino G, Brugaletta S, Munzel T, Feliz C, Schmidt G, Sabaté M, Onuma Y, van Geuns RJ, Gao RL, Menichelli M, Kereiakes DJ, Stone GW, Testa L, Kimura T, Abizaid A. Ellis SG, et al. Among authors: brugaletta s. JACC Cardiovasc Interv. 2018 Apr 9;11(7):638-644. doi: 10.1016/j.jcin.2017.11.042. JACC Cardiovasc Interv. 2018. PMID: 29622141 Free article.
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R; Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Valgimigli M, et al. Among authors: brugaletta s. Circulation. 2009 Jun 30;119(25):3215-22. doi: 10.1161/CIRCULATIONAHA.108.833236. Epub 2009 Jun 15. Circulation. 2009. PMID: 19528337 Clinical Trial.
ETHICA Award 2010: Antonio Colombo.
Serruys PW, Brugaletta S. Serruys PW, et al. Among authors: brugaletta s. EuroIntervention. 2010 Sep;6(4):431. doi: 10.4244/EIJ30V6I4A73. EuroIntervention. 2010. PMID: 20884428 No abstract available.
Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold.
Brugaletta S, Garcia-Garcia HM, Garg S, Gomez-Lara J, Diletti R, Onuma Y, van Geuns RJ, McClean D, Dudek D, Thuesen L, Chevalier B, Windecker S, Whitbourn R, Dorange C, Miquel-Hebert K, Sudhir K, Ormiston JA, Serruys PW. Brugaletta S, et al. Int J Cardiovasc Imaging. 2011 Jul;27(6):859-66. doi: 10.1007/s10554-010-9724-y. Epub 2010 Oct 13. Int J Cardiovasc Imaging. 2011. PMID: 20941544 Free article. Clinical Trial.
A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds.
Gomez-Lara J, Brugaletta S, Diletti R, Garg S, Onuma Y, Gogas BD, van Geuns RJ, Dorange C, Veldhof S, Rapoza R, Whitbourn R, Windecker S, Garcia-Garcia HM, Regar E, Serruys PW. Gomez-Lara J, et al. Among authors: brugaletta s. Eur Heart J. 2011 Feb;32(3):294-304. doi: 10.1093/eurheartj/ehq458. Epub 2010 Dec 1. Eur Heart J. 2011. PMID: 21123276 Free article.
Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial.
Sarno G, Bruining N, Onuma Y, Garg S, Brugaletta S, De Winter S, Regar E, Thuesen L, Dudek D, Veldhof S, Dorange C, Garcia-Garcia HM, Ormiston JA, Serruys PW. Sarno G, et al. Among authors: brugaletta s. Int J Cardiovasc Imaging. 2012 Jan;28(1):51-8. doi: 10.1007/s10554-010-9769-y. Epub 2011 Jan 7. Int J Cardiovasc Imaging. 2012. PMID: 21213050
385 results